Acumen Pharmaceuticals Stock Today
| ABOS Stock | USD 2.31 0.06 2.53% |
Performance0 of 100
| Odds Of DistressOver 55
|
Acumen Pharmaceuticals is selling for under 2.31 as of the 21st of November 2024; that is 2.53 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.25. Acumen Pharmaceuticals has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Acumen Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of July 2021 | Category Healthcare | Classification Health Care |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimers disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. The company has 60.08 M outstanding shares of which 1.45 M shares are presently shorted by private and institutional investors with about 7.19 trading days to cover. More on Acumen Pharmaceuticals
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Acumen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Daniel MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAcumen Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Acumen Pharmaceuticals' financial leverage. It provides some insight into what part of Acumen Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acumen Pharmaceuticals (ABOS) is traded on NASDAQ Exchange in USA. It is located in 427 Park Street, Charlottesville, VA, United States, 22902 and employs 51 people. Acumen Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 142.39 M. Acumen Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 60.08 M outstanding shares of which 1.45 M shares are presently shorted by private and institutional investors with about 7.19 trading days to cover.
Acumen Pharmaceuticals currently holds about 189.91 M in cash with (43.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Acumen Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAcumen Pharmaceuticals holds a total of 60.08 Million outstanding shares. The majority of Acumen Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Acumen Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Acumen Pharmaceuticals. Please pay attention to any change in the institutional holdings of Acumen Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Acumen Ownership Details
Acumen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Alyeska Investment Group, L.p. | 2024-06-30 | 939.6 K | |
| Geode Capital Management, Llc | 2024-06-30 | 812.1 K | |
| Hudson Bay Capital Management Lp | 2024-06-30 | 670 K | |
| Pathstone Holdings Llc | 2024-06-30 | 480.2 K | |
| State Street Corp | 2024-06-30 | 436.6 K | |
| Jane Street Group Llc | 2024-06-30 | 427.7 K | |
| Two Sigma Advisers, Llc | 2024-06-30 | 392.1 K | |
| Two Sigma Investments Llc | 2024-06-30 | 310.8 K | |
| Northern Trust Corp | 2024-09-30 | 308.9 K | |
| Ra Capital Management, Llc | 2024-06-30 | 14.9 M | |
| Sands Capital Ventures, Llc | 2024-09-30 | 3.4 M |
Acumen Pharmaceuticals Historical Income Statement
Acumen Stock Against Markets
Acumen Pharmaceuticals Corporate Management
| Julie Bockenstette | Ex HR | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Siew MS | Assistant Operations | Profile | |
| Robyn MA | Manager Communications | Profile |
Already Invested in Acumen Pharmaceuticals?
The danger of trading Acumen Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acumen Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acumen Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acumen Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.